The study, led by Qingtao Ni, Xiuyuan Yang, and Jingjing Bao, with corresponding author Chi Pan of The Affiliated Taizhou People’s Hospital of Nanjing Medical University, focuses on pyroptosis, a form of programmed cell death that has captivated cancer biologists in recent years. Unlike apoptosis, the quiet and orderly demise that most cell death research has traditionally centered on, pyroptosis is loud and destructive. Cells undergoing pyroptosis swell, rupture, and spill their contents into the surrounding tissue, triggering a potent inflammatory response. This explosive exit is orchestrated by members of the gasdermin family of proteins, which form pores in the cell membrane, and by inflammatory caspases such as caspase-1, which cleave those gasdermins into their active forms. The released cellular contents, including signaling molecules such as interleukin-1 beta and interleukin-18, can alert the immune system to danger. For tumor cells, this is often a catastrophic event, which is precisely why oncologists are interested in learning how to switch it on deliberately.

Yet the regulatory mechanisms governing pyroptosis in triple-negative breast cancer have remained poorly charted. To map them, the researchers began with an integrated bioinformatics analysis of publicly available gene expression datasets from the Gene Expression Omnibus, hunting for genes that are differentially expressed in breast cancer tissue compared with healthy tissue. From this screen, one gene stood out as a hub of malignant activity: MELK, short for maternal embryonic leucine zipper kinase. The team confirmed in clinical triple-negative breast cancer specimens that MELK is significantly upregulated in these tumors, and that elevated levels are associated with more advanced disease and poorer prognosis. Functionally, when the researchers manipulated MELK levels in triple-negative breast cancer cell lines, they found that the kinase actively promoted the hallmarks of cancer aggression: proliferation, migration, and invasion.

On the other side of the balance sat a microRNA. MicroRNAs are short, non-coding RNA molecules, roughly 22 nucleotides long, that do not encode proteins but instead regulate gene expression after transcription. They bind to complementary sequences in messenger RNA transcripts, marking them for degradation or blocking their translation into protein. A single microRNA can thereby tune the output of dozens of genes simultaneously. The microRNA in question here, miR-205-3p, was frequently found at reduced levels in triple-negative breast cancer samples, a pattern consistent with a tumor-suppressive role. When the researchers restored or elevated miR-205-3p in triple-negative breast cancer cell lines, the effect was striking: the cells underwent caspase-1-dependent pyroptosis, a conclusion supported by the appearance of cleaved fragments of both gasdermin D and gasdermin E, the executioner proteins of the pyroptotic pathway, as well as the release of interleukin-1 beta and interleukin-18 measured by Western blotting and enzyme-linked immunosorbent assay.

A natural question followed: was miR-205-3p simply silencing MELK directly? The answer, perhaps surprisingly, was no. Although MELK overexpression partially reversed the suppression of malignant behavior caused by miR-205-3p, the team’s experiments, including a dual-luciferase reporter assay, a standard technique for verifying direct binding between a microRNA and its target transcript, showed that miR-205-3p does not directly target MELK. Instead, the true direct target turned out to be a different molecule entirely: HSP90AB1, the heat shock protein 90 alpha family class B member 1, a molecular chaperone best known for stabilizing a wide array of client proteins inside the cell. The reporter assays confirmed that miR-205-3p binds directly to HSP90AB1 transcripts and represses their expression.

This discovery reframed the entire regulatory architecture. HSP90AB1, it emerged, sits at the center of a tug-of-war between the tumor-suppressive microRNA and the oncogenic kinase. The researchers found that MELK positively regulates HSP90AB1, enhancing its expression, and that this enhancement serves to inhibit the pyroptotic pathway. In other words, MELK protects triple-negative breast cancer cells from inflammatory self-destruction by keeping the chaperone abundant, while miR-205-3p promotes pyroptosis by stripping that protection away. When miR-205-3p represses HSP90AB1, the downstream gasdermin D and gasdermin E cleavage cascade is unleashed, and the cell dies by pyroptosis. When MELK is abundant and drives HSP90AB1 upward, the miR-205-3p/HSP90AB1/GSDMD axis is suppressed, and the cell survives to proliferate, migrate, and invade.

The interplay between these two regulators through their shared target ultimately determines cellular fate, the authors conclude. This kind of indirect antagonism, in which a microRNA and a kinase converge on a common downstream effector rather than on each other, adds a layer of nuance to how researchers think about microRNA-mediated tumor suppression. It also helps explain why MELK has repeatedly surfaced in cancer studies as a driver of malignancy: beyond its established roles in cell cycle control and signaling, it appears to function as a critical upstream brake on pyroptosis, keeping tumor cells from triggering the inflammatory form of death that would otherwise expose them to immune attack.

The therapeutic implications are considerable. Triple-negative breast cancer has long been an attractive candidate for immunotherapy and other novel approaches precisely because its inflammatory microenvironment, when it exists, correlates with better responses. If pyroptosis can be pharmacologically induced in these tumors, the resulting release of damage-associated molecular patterns and inflammatory interleukins could convert a cold tumor into a hot one, recruiting immune cells to the site of disease. The newly described miR-205-3p/HSP90AB1/GSDMD axis offers several potential intervention points: restoring miR-205-3p activity, inhibiting MELK, or directly targeting HSP90AB1 function. MELK inhibitors have already attracted attention in drug development pipelines, and the present study provides a fresh mechanistic rationale for exploring them in triple-negative breast cancer, not merely as anti-proliferative agents but as sensitizers of immunogenic cell death.

As with all laboratory studies, the path from cell culture to clinic is long. The experiments relied on established triple-negative breast cancer cell lines and clinical specimens, and the authors note that the work was approved by the Ethical Committee of Jiangsu Taizhou People’s Hospital with written informed consent from participants. Delivering microRNA mimics to tumors remains a formidable delivery challenge, and the precise consequences of triggering pyroptosis in a living tumor, where inflammatory signals can sometimes fuel growth as easily as they can ignite immune clearance, will require careful evaluation in animal models and, eventually, clinical trials. Still, the study adds an important piece to the puzzle of why triple-negative breast cancer cells resist death, and it identifies a concrete molecular switch—HSP90AB1, poised between a protective kinase and a lethal microRNA—that future therapies might one day flip. For patients facing the hardest-to-treat form of breast cancer, that switch represents a genuinely new lead.

Subject of Research: The regulatory mechanism by which miR-205-3p induces pyroptosis in triple-negative breast cancer through HSP90AB1 and antagonism of MELK.

Article Title: miR-205-3p induces pyroptosis in triple-negative breast cancer by targeting HSP90AB1 and antagonizing MELK

Article References: Ni, Q., Yang, X., Bao, J., Yi, T., & Pan, C. (2026). miR-205-3p induces pyroptosis in triple-negative breast cancer by targeting HSP90AB1 and antagonizing MELK. BMC Cancer. https://doi.org/10.1186/s12885-026-17028-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17028-5

Keywords: triple-negative breast cancer, pyroptosis, miR-205-3p, HSP90AB1, MELK, gasdermin D, gasdermin E, caspase-1, microRNA, tumor suppression, cell death, BMC Cancer